Tito Serafini
Gründer bei ATRECA, INC.
Vermögen: 27 736 $ am 30.04.2024
Profil
Tito A.
Serafini is the founder.
He founded Renovis, Inc. in 2000, where he held the title of Chief Discovery Scientist.
He also founded Atreca, Inc. in 2010, where he holds the title of Director.
Currently, Dr. Serafini is the Director at Anagenex, Inc. In the past, he worked as an Independent Director at Brookline Capital Acquisition Corp.
and as a Faculty Member at the University of California, Berkeley.
From 2009 to 2011, he served as the Chief Scientific Officer at Nuon Therapeutics, Inc. Dr. Serafini completed his undergraduate degree at Case Western Reserve University in 1985 and obtained his doctorate degree from Stanford University School of Medicine in 1991.
Bekannte Unternehmensbeteiligungen
| Unternehmen | Datum | Anzahl der Aktien | Bewertung | Datum der Bewertung |
|---|---|---|---|---|
ATRECA, INC. CLASS A
0,84% | 11.04.2024 | 322 511 ( 0,84% ) | 27 736 $ | 30.04.2024 |
Aktive Positionen von Tito Serafini
| Unternehmen | Position | Beginn |
|---|---|---|
| ATRECA, INC. | Gründer | 11.06.2010 |
Anagenex, Inc.
 Anagenex, Inc. Packaged SoftwareTechnology Services Anagenex, Inc. is a company that uses high quality, large-scale data generation and AI to discover the next generation of small molecule medicines. Anagenex is based in San Francisco, CA. The company's platform leverages AI to design and synthesize hundreds of millions of target-specific compounds for testing in two weeks. The company's pipeline is focused on synthetic lethal oncology. The company was founded by Nicolas Tilmans and he has been the CEO since incorporation. | Direktor/Vorstandsmitglied | - |
Ehemalige bekannte Positionen von Tito Serafini
| Unternehmen | Position | Ende |
|---|---|---|
Nuon Therapeutics, Inc.
 Nuon Therapeutics, Inc. Pharmaceuticals: MajorHealth Technology Nuon Therapeutics Inc. develops therapies to treat inflammation and neurological diseases. The company focuses on the development and commercialization of new therapies for autoimmune disease and inflammation includes rheumatoid arthritis and multiple sclerosis. Nuon Therapeutics was founded by Kim Puloma Kamdar, Marc Feldmann, Lawrence J. Steinman and Michael Selley in 2006 and is headquartered in San Mateo, CA. | Technik-/Wissenschafts-/F&E-Leiter | 01.01.2011 |
Renovis, Inc.
 Renovis, Inc. Pharmaceuticals: MajorHealth Technology Renovis, Inc. develops pharmaceutical products. The company discovers, develops, and commercializes novel therapeutics for neurological and inflammatory diseases. It is headquartered in San Francisco, CA | Gründer | - |
| BROE CAPI | Direktor/Vorstandsmitglied | - |
| University of California, Berkeley | Corporate Officer/Principal | - |
Ausbildung von Tito Serafini
| Case Western Reserve University | Undergraduate Degree |
| Stanford University School of Medicine | Doctorate Degree |
Erfahrungen
Besetzte Positionen
Aktive
Inaktive
Börsennotierte Unternehmen
Private Unternehmen
Beziehungen
Beziehungen ersten Grades
Unternehmen ersten Grades
Herr
Frau
Aufsichtsräte
Führungskräfte
Unternehmensverbindungen
| Börsennotierte Unternehmen | 1 |
|---|---|
| ATRECA, INC. | Health Technology |
| Private Unternehmen | 4 |
|---|---|
Renovis, Inc.
Renovis, Inc. Pharmaceuticals: MajorHealth Technology Renovis, Inc. develops pharmaceutical products. The company discovers, develops, and commercializes novel therapeutics for neurological and inflammatory diseases. It is headquartered in San Francisco, CA | Health Technology |
Nuon Therapeutics, Inc.
Nuon Therapeutics, Inc. Pharmaceuticals: MajorHealth Technology Nuon Therapeutics Inc. develops therapies to treat inflammation and neurological diseases. The company focuses on the development and commercialization of new therapies for autoimmune disease and inflammation includes rheumatoid arthritis and multiple sclerosis. Nuon Therapeutics was founded by Kim Puloma Kamdar, Marc Feldmann, Lawrence J. Steinman and Michael Selley in 2006 and is headquartered in San Mateo, CA. | Health Technology |
Brookline Capital Acquisition Corp.
 Brookline Capital Acquisition Corp. Financial ConglomeratesFinance Brookline Capital Acquisition Corp. is a blank check company which intends to focus its search on companies in the life sciences industry. It was formed for the purpose of entering into a merger, share exchange, asset acquisition, stock purchase, recapitalization, reorganization, or other similar business combination with one or more businesses or entities. The company was founded on May 27, 2020 and is headquartered in New York, NY. | Finance |
Anagenex, Inc.
Anagenex, Inc. Packaged SoftwareTechnology Services Anagenex, Inc. is a company that uses high quality, large-scale data generation and AI to discover the next generation of small molecule medicines. Anagenex is based in San Francisco, CA. The company's platform leverages AI to design and synthesize hundreds of millions of target-specific compounds for testing in two weeks. The company's pipeline is focused on synthetic lethal oncology. The company was founded by Nicolas Tilmans and he has been the CEO since incorporation. | Technology Services |
